Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 8/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiagabine SCHEMBL18496408 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL17493682 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL5164417 | 1.00 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL1527642 | 0.99 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3272861 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL342814 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL34653 | 0.99 | SLC6A1 (1.00) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL7346237 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3958156 | 0.98 | SLC6A1 (0.98) | SLC6A1PTGS1PDE4AALDH1A1LMNA | |
| Tiagabine SCHEMBL3243472 | 0.95 | SLC6A1 (0.90) | SLC6A1PTGS1PDE4AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2210 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250201404-A1 | RNA-BASED METHOD FOR SEIZURE ASSESSMENT | MOREHOUSE SCHOOL OF MEDICINE | 2025-06-19 | — | — | US | claimed |
| CN-119798263-A | Ticagrelor acetyl derivative and preparation method thereof | 南通常佑药业科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119790152-A | Treatment of neurological disorders using modulators of UNC13A gene transcripts | 奎里斯公司 | 2025-04-08 | — | — | CN | claimed |
| CN-119522282-A | Splice transducer antisense oligonucleotides with modified backbone chemistry | 奎里斯公司 | 2025-02-25 | — | — | CN | claimed |
| US-20250051766-A1 | TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS | QURALIS CORPORATION | 2025-02-13 | — | — | US | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2023102242-A9 | SPLICE SWITCHER ANTISENSE OLIGONUCLEOTIDES WITH MODIFIED BACKBONE CHEMISTRIES | QURALIS CORPORATION (US) | 2024-10-31 | — | — | WO | claimed |
| EP-4441226-A2 | SPLICE SWITCHER ANTISENSE OLIGONUCLEOTIDES WITH MODIFIED BACKBONE CHEMISTRIES | Quralis Corporation (US) | 2024-10-09 | — | — | EP | claimed |
| EP-4441225-A2 | TREATMENT OF NEUROLOGICAL DISEASES USING MODULATORS OF UNC13A GENE TRANSCRIPTS | Quralis Corporation (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2002000221-A1 | ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2002-01-03 | — | — | WO | claimed |
| US-5958951-A | ANTIEPILEPIC AGENTS | NOVO NORDISKIALS (DK) | 1999-09-28 | — | — | US | claimed |
| CN-1225094-A | Improved forms of R (-) -N- (4, 4-di (3-methylthiophen-2-yl) but-3-enyl) -3-piperidinecarboxylic acid hydrochloride | NOVO NORDISK AS (DK) | 1999-08-04 | — | — | CN | claimed |
| EP-0579681-B1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK AS (DK) | 1999-06-02 | — | — | EP | claimed |
| EP-0906309-A1 | MODIFIED FORM OF THE R(-)-N-(4,4-DI(3-METHYLTHIEN-2-YL)BUT-3-ENYL)-NIPECOTIC ACID HYDROCHLORIDE | NOVO NORDISK A/S (DK) | 1999-04-07 | — | — | EP | claimed |
| US-5866590-A | ASCORBIC ACID OR A-TOCOPHEROL AND ASCORBYL PALMITATE AS OXIDATIVE STABILIZERS | NOVO NORDISK A/S (DK) | 1999-02-02 | — | — | US | claimed |
| WO-1997047619-A1 | MODIFIED FORM OF THE R(-)-N-(4,4-DI(3-METHYLTHIEN-2-YL)BUT-3-ENYL)-NIPECOTIC ACID HYDROCHLORIDE | NOVO NORDISK A/S (DK) | 1997-12-18 | — | — | WO | claimed |
| US-5354760-A | Antiepileptic agents; acid-catalyzed hydrolysis of ethyl R-)-N-(4,4-di(3-methylthien-2-yl)but-3-3nyl)nipecotate hydrochloride; crystallization and precipitation from an aqueous solution to form the monohydrate | NOVO NORDISK A/S (DK) | 1994-10-11 | — | — | US | claimed |
| EP-0579681-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-01-26 | — | — | EP | claimed |
| WO-1992017473-A1 | CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1992-10-15 | — | — | WO | claimed |